These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26748241)

  • 1. mTOR inhibitor temsirolimus and MEK1/2 inhibitor U0126 promote chromosomal instability and cell type-dependent phenotype changes of glioblastoma cells.
    Stepanenko AA; Andreieva SV; Korets KV; Mykytenko DO; Baklaushev VP; Chekhonin VP; Dmitrenko VV
    Gene; 2016 Mar; 579(1):58-68. PubMed ID: 26748241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor.
    Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H
    Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combination of rapamycin and MAPK inhibitors enhances the growth inhibitory effect on Nara-H cells.
    Nakamura O; Hitora T; Yamagami Y; Mori M; Nishimura H; Horie R; Yamaguchi K; Yamamoto T
    Int J Mol Med; 2014 Jun; 33(6):1491-7. PubMed ID: 24676456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
    Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
    J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation.
    Zohrabian VM; Forzani B; Chau Z; Murali R; Jhanwar-Uniyal M
    Anticancer Res; 2009 Jan; 29(1):119-23. PubMed ID: 19331140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide promotes genomic and phenotypic changes in glioblastoma cells.
    Stepanenko AA; Andreieva SV; Korets KV; Mykytenko DO; Baklaushev VP; Huleyuk NL; Kovalova OA; Kotsarenko KV; Chekhonin VP; Vassetzky YS; Avdieiev SS; Dmitrenko VV
    Cancer Cell Int; 2016; 16():36. PubMed ID: 27158244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged extracellular signal-regulated kinase 1/2 activation during fibroblast growth factor 1- or heregulin beta1-induced antiestrogen-resistant growth of breast cancer cells is resistant to mitogen-activated protein/extracellular regulated kinase kinase inhibitors.
    Thottassery JV; Sun Y; Westbrook L; Rentz SS; Manuvakhova M; Qu Z; Samuel S; Upshaw R; Cunningham A; Kern FG
    Cancer Res; 2004 Jul; 64(13):4637-47. PubMed ID: 15231676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crosstalk between the PI3K/mTOR and MEK/ERK pathways involved in the maintenance of self-renewal and tumorigenicity of glioblastoma stem-like cells.
    Sunayama J; Matsuda K; Sato A; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
    Stem Cells; 2010 Nov; 28(11):1930-9. PubMed ID: 20857497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
    Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
    Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
    Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
    Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
    Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
    Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant anti-proliferation of human endometrial cancer cells by combined treatment with a selective COX-2 inhibitor NS398 and specific MEK inhibitor U0126.
    Gao J; Niwa K; Takemura M; Sun W; Onogi K; Wu Y; Seishima M; Mori H; Tamaya T
    Int J Oncol; 2005 Mar; 26(3):737-44. PubMed ID: 15703831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of MEK and mammalian target of rapamycin abolishes phosphorylation of cyclin-dependent kinase 4 in glioblastoma cell lines and prevents their proliferation.
    Paternot S; Roger PP
    Cancer Res; 2009 Jun; 69(11):4577-81. PubMed ID: 19458076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic inhibition of RAF-->MEK-->ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kip1.
    Gysin S; Lee SH; Dean NM; McMahon M
    Cancer Res; 2005 Jun; 65(11):4870-80. PubMed ID: 15930308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key role of MEK/ERK pathway in sustaining tumorigenicity and in vitro radioresistance of embryonal rhabdomyosarcoma stem-like cell population.
    Ciccarelli C; Vulcano F; Milazzo L; Gravina GL; Marampon F; Macioce G; Giampaolo A; Tombolini V; Di Paolo V; Hassan HJ; Zani BM
    Mol Cancer; 2016 Feb; 15():16. PubMed ID: 26897742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme.
    Albert L; Karsy M; Murali R; Jhanwar-Uniyal M
    Cancer Genomics Proteomics; 2009; 6(5):255-61. PubMed ID: 19996130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential sensitivity of chemoresistant neuroblastoma subtypes to MAPK-targeted treatment correlates with ERK, p53 expression, and signaling response to U0126.
    Eppstein AC; Sandoval JA; Klein PJ; Woodruff HA; Grosfeld JL; Hickey RJ; Malkas LH; Schmidt CM
    J Pediatr Surg; 2006 Jan; 41(1):252-9. PubMed ID: 16410143
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mitogen-activated/extracellular signal-regulated kinase kinase 1/2 inhibitor U0126 induces glial fibrillary acidic protein expression and reduces the proliferation and migration of C6 glioma cells.
    Lind CR; Gray CW; Pearson AG; Cameron RE; O'Carroll SJ; Narayan PJ; Lim J; Dragunow M
    Neuroscience; 2006 Sep; 141(4):1925-33. PubMed ID: 16809005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.